With a European approval for chronic kidney disease nod in hand, Boeringer Ingelheim and Eli Lilly’s Jardiance is looking to catch up to AstraZeneca’s Farxiga in this use and continue growing its r | After recent label expansions in the U.S. and Europe paid off with a sizable sales increase for Jardiance, the drug has added a third use to its European label. An FDA approval in chronic kidney disease could follow this year.
